OpenNashPodcasts

Person

Ben Comer

Ben Comer appears on the Business Of Biotech podcast in two episodes: one on using genetics to discover new treatments with Regeneron Genetics Center's Aris Baras, and one on modernizing clinical trial operations with Merck's Jennifer Sheller.

In the Regeneron episode, the statements say Aris Baras joined Regeneron in 2011, helped found its genetics center in 2013, and that its database holds over 3 million sequenced exomes. The Merck episode covers Jennifer Sheller joining Merck in 2017 and Merck's nearly $18 billion in research spending in 2024. Ben Comer also says Merck has a small-molecule product targeting PCSK9.

2 episodes · 5 quoted claims

Aris Baras joined Regeneron in 2011 and helped found the Regeneron Genetics Center in 2013.

“Aris joined Regeneron in 2011 and helped found the Regeneron Genetics Center, or RGC, in 2013.”

Business Of Biotech · 0:00:03

The Regeneron Genetics Center database contains over 3 million sequenced exomes from collaborations with more than 150 global partners.

“The RGC database now contains over 3 million sequenced exomes through collaborations with more than 150 global partners.”

Business Of Biotech · 0:00:03

Ben Comer says Merck has a small-molecule product targeting PCSK9.

“Merck's got a small molecule product now targeting PCSK9.”

Business Of Biotech · 0:09:14

Merck invested nearly $18 billion in research and development in 2024 and conducts trials in over 60 countries at more than 21,000 sites.

“a company that invested nearly $18 billion in R &D in 2024 and conducts trials in over 60 countries at more than 21 ,000 trial sites”

Business Of Biotech · 0:00:06

Jennifer Sheller joined Merck in 2017 and initially worked on integrating acquired companies' R&D activities into Merck's operations.

“You joined Merck in 2017, Jen, and initially, I think, worked on integrating acquired companies' R &D activities into Merck's R &D operations.”

Business Of Biotech · 0:16:33